Net clinical benefit of dabigatran vs. warfarin in venous thromboembolism: analyses from RE-COVER®, RE-COVER™ II, and RE-MEDY™
Crossref DOI link: https://doi.org/10.1007/s11239-017-1479-z
Published Online: 2017-02-16
Published Print: 2017-05
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Feuring, Martin
Schulman, Sam
Eriksson, Henry
Kakkar, Ajay J.
Schellong, Sebastian
Hantel, Stefan
Schueler, Elke
Kreuzer, Jörg
Goldhaber, Samuel Z.
Funding for this research was provided by:
Boehringer Ingelheim
License valid from 2017-02-16